Skip to content

AmStErdam Cohort StUdy of Patients at Risk for VEntricular Arrhythmias

AmStErdam Cohort StUdy of Patients at Risk for VEntricular Arrhythmias - SECURE

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53817
Enrollment
245
Registered
2023-10-02
Start date
2024-08-15
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sudden cardiac death Ventricular arrhythmia

Interventions

None listed

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients with a primary prevention ICD, according to current EU guidelines - Patients with no prior documented treated or untreated sustained ventricular arrhythmias - >=18 years of age

Exclusion criteria

Exclusion criteria: - Transvenous ICD implanted less than 3 months prior to inclusion - Contra-indications for venepunctures - CRT-D patients - Patients with an ICD indication based on a channelopathy

Design outcomes

Primary

MeasureTime frame
The expression of biomarkers in the serum of patients with and without appropriate therapy.

Secondary

MeasureTime frame
To determine novel biomarkers that may be associated with the onset of ventricular arrhythmias. This is done through proteomics. The patients with appropriate therapy are matched with patients without appropriate therapy. Subsequently, the protein profile is determined in both groups in order to see whether there are proteins that are elevated in the group with an arrhythmia and not in the group without an arrhythmia.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)